Brentuximab Vedotin Drug Aliquot | Anti-CD30 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Ipilimumab are now available as research consumables.

Brentuximab vedotin drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of brentuximab vedotin drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Adcetris Brentuximab Vedotin Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Adcetris® / Brentuximab Vedotin Reference Product

Drug nameAdcetris®
INNBrentuximab Vedotin
API typeBrentuximab Vedotinis an antibody-drug conjugate composed of a CD30-directed monoclonal antibody (recombinant chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule agent monomethyl auristatin E (MMAE)
Pharmacotherapeutic group
Antineoplastic agents
ATC code
L01XC12
Target of antibody
CD-30
General functionThe monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells. The cytotoxic molecule then enters the cancer cells and stops them from dividing, and the cancer cells eventually die.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Brentuximab vedotin is an ADC that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Antineoplastic agents; other Cardiac electrophysiology
Forty-six (46) patients with CD30-expressing haematologic malignancies were evaluable of the
52 patients who received 1.8 mg/kg of brentuximab vedotin every 3 weeks as part of a phase 1,
single-arm, open-label, multicenter cardiac safety study. The primary objective was to evaluate the
effect of brentuximab vedotin on cardiac ventricular re-polarization and the predefined primary
analysis was the change in QTc from baseline to multiple time points in Cycle 1.
The upper 90% confidence interval (CI) around the mean effect on QTc was < 10 msec at each of the
Cycle 1 and Cycle 3 post-baseline time points. These data indicate the absence of clinically relevant
QT prolongation due to brentuximab vedotin administered at a dose of 1.8 mg/kg every 3 weeks in
patients with CD30-expressing malignancies
Original license holder
Takeda Pharma A/S
Marketing authorisation numbers
EU/1/03/256/022
Marketing authorisation holder
Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark
Name of the manufacturer of the biological active substance
Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark
Name and address of the manufacturer(s) responsible for batch releaseTakeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark
Max shelf life
48 months
Storage conditions
2°C – 8°C
List of excipients
Citric acid monohydrate
Sodium citrate dihydrate
α,α-Trehalose dihydrate
Polysorbate 80

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.